

Joseph Mikhael

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2236518/publications.pdf>

Version: 2024-02-01

18
papers

1,241
citations

840119

11
h-index

839053

18
g-index

18
all docs

18
docs citations

18
times ranked

1587
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. <i>Blood</i> , 2017, 130, 2401-2409.	0.6	403
2	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet, The</i> , 2021, 397, 2361-2371.	6.3	177
3	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
4	Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. <i>American Journal of Hematology</i> , 2019, 94, 1176-1184.	2.0	112
5	A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>Blood</i> , 2019, 134, 123-133.	0.6	82
6	Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 41.	2.8	80
7	Treatment Options for Triple-class Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 1-7.	0.2	73
8	A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. <i>Blood Cancer Journal</i> , 2021, 11, 89.	2.8	49
9	A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2020, 34, 3298-3309.	3.3	37
10	Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study. <i>Blood</i> , 2016, 128, 488-488.	0.6	27
11	Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. <i>Blood Cancer Journal</i> , 2018, 8, 86.	2.8	16
12	Digital Health for Patients With Multiple Myeloma: An Unmet Need. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1096-1105.	1.0	12
13	COVID-19 and myeloma: what are the implications for now and in the future?. <i>British Journal of Haematology</i> , 2020, 190, 173-178.	1.2	9
14	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. <i>American Journal of Hematology</i> , 2023, 98, .	2.0	6
15	Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. <i>Blood Advances</i> , 2022, 6, 4506-4515.	2.5	4
16	Turn off the Tap! The Need for Induction Therapy for AL Amyloidosis Before Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, e1-e2.	2.0	3
17	Real-world renal function among patients with multiple myeloma in the United States. <i>Blood Cancer Journal</i> , 2021, 11, 99.	2.8	3
18	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210884.	1.1	2